The abstract is read at the publisher; the summary is JClub's.
Once-daily orforglipron in Japanese adults with obesity disease produced greater bodyweight loss at week 72 than placebo, with the largest mean change of -8·7% at 12 mg.
- Why it matters: The trial addresses whether an oral GLP-1 receptor agonist can deliver effective weight reduction and acceptable tolerability in Japanese adults meeting obesity disease criteria.
- What they did: In ATTAIN-J, 238 adults were randomized 1:1:1:1 to orforglipron 6 mg, 12 mg, or 36 mg, or placebo, and co-primary endpoints were assessed through week 72. Safety was evaluated in participants receiving at least one dose.
- The result: Mean bodyweight change at week 72 was -5·9% (6 mg), -8·7% (12 mg), and -7·9% (36 mg) versus -0·6% with placebo (all p<0·0001), and ≥5% loss occurred in 45·6%, 60·8%, and 58·8% versus 15·2%; adverse events were mostly mild-to-moderate gastrointestinal symptoms.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.